March 28, 2019 09:39 AM EDTUpdated 02:02 PM
People

Sure Hervé Hop­penot took a big cut in com­pen­sa­tion af­ter a pipeline dis­as­ter. But he still outscored the on­ly woman on the list

John Carroll

Editor & Founder

Af­ter a bru­tal year at the helm, In­cyte CEO Hervé Hop­penot took a big cut in an­nu­al com­pen­sa­tion for 2018 — but he still made more than GSK CEO Em­ma Walm­s­ley.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times